Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix to Receive $4.9M from Private Placement

NEW YORK, May 20 - CombiMatrix parent Acacia Research announced a private placement of 2.4 million units of its common stock today, out of which CombiMatrix will receive about $4.9 million.


The stock units, which include one share of Acacia Research-CombiMatrix stock and one-half warrant, are being purchased for $2.20 per unit, for a total of $5.28 million.


The company plans to use its funding to give it "the flexibility to take advantage of current opportunities," CEO Amit Kumar said in a statement.


CombiMatrix, founded in 1995, was funded with $36 million in August 2000. Acacia Research, which has since bought a majority stake of the company's equity, was the lead investor in the VC funding, anteing in $17.5 million with additional investments from a mix of Silicon Valleyand New Yorkventure capital investors.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.